Evolution of therapies for chronic myelogenous leukemia.

  title={Evolution of therapies for chronic myelogenous leukemia.},
  author={F{\'a}bio Pires de Souza Santos and Hagop M Kantarjian and Alfonso Quint{\'a}s-Cardama and Jorge E. Cortes},
  journal={Cancer journal},
  volume={17 6},
The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed for CML, and it led to high rates of complete cytogenetic responses and improved survival for patients with this disease. However, approximately 35% of patients in chronic phase treated with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…